

HR 946

ORPHAN Cures Act

Congress: 119 (2025–2027, Current)

Chamber: House

Policy Area: Health

Introduced: Feb 4, 2025

Current Status: Sponsor introductory remarks on measure. (CR H535-536)

Latest Action: Sponsor introductory remarks on measure. (CR H535-536) (Feb 6, 2025)

Official Text: <https://www.congress.gov/bill/119th-congress/house-bill/946>

Sponsor

Name: Rep. Joyce, John [R-PA-13]

Party: Republican • **State:** PA • **Chamber:** House

Cosponsors (18 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Bilirakis, Gus M. [R-FL-12]	R · FL		Feb 4, 2025
Rep. Davis, Donald G. [D-NC-1]	D · NC		Feb 4, 2025
Rep. Gottheimer, Josh [D-NJ-5]	D · NJ		Feb 4, 2025
Rep. Hern, Kevin [R-OK-1]	R · OK		Feb 4, 2025
Rep. Hudson, Richard [R-NC-9]	R · NC		Feb 4, 2025
Rep. Keating, William R. [D-MA-9]	D · MA		Feb 4, 2025
Rep. Miller-Meeks, Mariannette [R-IA-1]	R · IA		Feb 4, 2025
Rep. Peters, Scott H. [D-CA-50]	D · CA		Feb 4, 2025
Rep. Thanedar, Shri [D-MI-13]	D · MI		Feb 4, 2025
Rep. Bynum, Janelle [D-OR-5]	D · OR		Apr 7, 2025
Rep. Kean, Thomas H. [R-NJ-7]	R · NJ		Apr 7, 2025
Rep. Smucker, Lloyd [R-PA-11]	R · PA		Apr 7, 2025
Rep. Titus, Dina [D-NV-1]	D · NV		Apr 7, 2025
Rep. Dunn, Neal P. [R-FL-2]	R · FL		May 20, 2025
Rep. Salinas, Andrea [D-OR-6]	D · OR		May 20, 2025
Rep. Crenshaw, Dan [R-TX-2]	R · TX		Jun 12, 2025
Rep. Gray, Adam [D-CA-13]	D · CA		Jun 12, 2025
Rep. Bresnahan, Robert P. [R-PA-8]	R · PA		Sep 30, 2025

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Feb 4, 2025
Ways and Means Committee	House	Referred To	Feb 4, 2025

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
119 S 1862	Related bill	May 22, 2025: Read twice and referred to the Committee on Finance. (text: CR S3119)

Summary (as of Feb 4, 2025)

Optimizing Research Progress Hope And New Cures Act or the ORPHAN Cures Act

This bill modifies certain provisions under the Medicare Drug Price Negotiation Program with respect to orphan drugs.

The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. The program does not apply to orphan drugs that are approved to treat only one rare disease or condition.

The bill modifies these provisions so as to exclude any period in which a drug was an orphan drug from market approval calculations. It also excludes orphan drugs that are approved to treat more than one rare disease or condition from the program.

